IMPEL PHARMACEUTICALS INC: Nasdaq/NYSE listing notice — Impel Pharmaceuticals receives Nasdaq delisting; stock to move to OTC

IMPEL PHARMACEUTICALS INC

Delisting due to failure to meet $50M MVLS and $15M MVPHS continued listing rules.
Trading suspended at opening of business on December 18, 2023.
Common stock expected to begin trading on the over-the-counter (OTC) market.
No assurances that OTC trading will commence or be maintained given risks.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

IMPEL PHARMACEUTICALS INC received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C), 5450(b)(2)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(C), 5450(b)(2)(A)

Exact text from the filing

April 5, 2023, and that, for the for the 30-business day period ended April 5, 2023, the Company had not met the $50 million minimum market value of listed securities required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(A) (the “ MVLS Rule ” and together with the MVPHS Rule, the “ Rules ”). As provided in the Nasdaq rules, the Company had 180 calendar days, or until October 9, 2023, to regain compliance. The Company did not regain compliance with such applicable Rules prior to October 9, 2023, and on October 16, 2023, the Company requested a hearing to rema

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-297146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.